Laboratory Testing and Monitoring for Patients Starting Aripiprazole

Baseline Laboratory Tests Required

The American Academy of Child and Adolescent Psychiatry recommends obtaining fasting blood glucose, complete blood count, comprehensive metabolic panel including liver function tests, lipid profile, and body mass index before starting aripiprazole, with ongoing monitoring of metabolic parameters monthly for 3 months then quarterly thereafter 1
Fasting blood glucose (or HbA1c if fasting sample unavailable) should be screened to assess the risk of diabetes mellitus, as atypical antipsychotics including aripiprazole are associated with hyperglycemia risk 1
Lipid profile (total cholesterol, LDL, HDL, triglycerides) should be established at baseline to monitor potential metabolic changes 1
Body mass index (BMI) and waist circumference measurement should be taken, as weight gain is a known adverse effect of atypical antipsychotics 1
Complete blood count (CBC) should be assessed to evaluate baseline hematologic parameters, particularly important if the patient has a history of low white blood cell count 1
Comprehensive metabolic panel including liver function tests (ALT, AST, alkaline phosphatase, bilirubin), blood urea nitrogen, serum creatinine, and electrolytes (sodium, potassium, calcium, magnesium) should be obtained 1
Blood pressure measurement should be taken to establish baseline cardiovascular parameters 1
Pregnancy test should be performed for women of childbearing potential before initiating therapy 1

BMI measurement should be taken monthly for the first 3 months to detect early weight gain 1
Blood pressure should be monitored at each visit during the initial treatment phase 1
BMI should be measured quarterly after the initial 3-month period 1
Blood pressure, fasting glucose, and lipids should be followed up after 3 months, then yearly thereafter 1

The American Psychiatric Association guidelines emphasize that atypical antipsychotics as a class are associated with significant metabolic problems including type 2 diabetes, hyperlipidemia, and weight gain 1

Failure to obtain baseline values makes it impossible to determine whether abnormalities are treatment-emergent or pre-existing 1
Inadequate frequency of weight monitoring in the first 3 months when metabolic changes are most likely to emerge 1
Not screening for pregnancy in women of childbearing potential before initiation 1